

### SUMMARY

Flu A is rapidly declining

RSV is on the rise

### NEW

Fecal lactoferrin test is system-wide and replaces fecal leukocytes

### A Publication of Geisinger Medical Laboratories 2015 Vol. (4):1-4, February 16, 2015

**RESPView Pathogen Surveillance 2014-2015: Influenza A is showing a marked decline from previous weeks. The predominant virus is still influenza A (41%) followed by respiratory syncytial virus (35%) and rhinovirus (8%). See Tables.**




**10X Essentials: Fecal Lactoferrin Test (FLEIA) replaces Fecal Leukocyte Test (FLEU):** Effective March 1, 2015, Microbiology at Geisinger Medical Laboratories will adopt an improved test for inflammatory diarrhea.

- **FLEIA Improvements to Care: (See page 4, references 1-14)**
- Fecal lactoferrin (FLEIA) is a non-invasive iron-binding glycoprotein biomarker **expressed during inflammation** by the granules of activated neutrophils in the gut and by most mucosal membranes. Other white blood cells do NOT contain lactoferrin.
- Lactoferrin is proportional to the flux of neutrophils and is documented to improve detection of all inflammatory diarrhea, including *C. difficile* and some other bacterial infections. **It is stable in stool and not prone to degradation as are whole neutrophils.**
- Increased fecal lactoferrin is a sensitive and specific surrogate marker for inflammatory bowel diseases (IBD) in adults and children with chronic diarrhea and pain, and is predictive of clinical flares and relapse.
- It is also elevated in Crohn's disease (CD) and predictive of post-surgical recurrence, but is not elevated in irritable bowel syndrome (IBS).
- It also measures disease activity and severity of colitis and ulcerative colitis. It can predict relapse, and identify high-risk groups of acute severe colitis patients and avoid the use of ultrasound or colonoscopy, the latter of which is invasive, costly and has poor patient acceptability.
- **You MUST submit a FRESH stool in a sterile cup for Fecal Lactoferrin (FLEIA) Testing.**
- **Transport:** FLEIA is stable at 2-8 degrees C for up to one week
- **CPT code** FLEIA = 83630
- **Test sites:** Performed once per shift at GMC (Danville), GLH (Lewistown), and HSHS (Holy Spirit Health System).
- **Reporting:** Positive = Lactoferrin detected; Negative = No lactoferrin detected
- **Limitations:** Neutropenic individuals may produce false negative lactoferrin assays, as will some samples from pure ileal Crohn's disease


If you have any questions, please contact the Doctoral Directors, pager 8600, Technical Specialist, pager 8181.  
For newsletter questions, contact Christy Attinger, (570) 271-6338

# GML RespVIEW 2014-2015



CDC Respiratory Week, 2014-2015	49	50	51	52	1	2	3	4	5	6	7
adenovirus	11	8	10	17	14	23	14	16	13	12	9
coronavirus	14	17	28	21	27	29	29	16	9	15	13
hum. metapneumovirus	2	3	7	7	18	22	19	24	22	11	14
influenza A	21	33	140	265	346	331	371	397	328	202	143
influenza B	2	1	2	1	3	2	4	10	4	6	7
parainfluenza	17	16	16	17	18	26	24	13	13	9	10
respiratory syncytial virus	7	15	27	40	60	80	84	112	127	134	120
rhinovirus	40	32	48	48	67	62	52	51	37	44	29
◆ % Positive Rollup (right axis)	35%	41%	50%	58%	55%	51%	51%	54%	51%	49%	45%

## Weekly GML RespVIEW: Respiratory Virus Distribution CDC Week 7, 2014-2015



#### Fecal Lactoferrin Reference List

1. **Boone, J. H., L. R. Archbald-Pannone, K. N. Wickham, R. J. Carman, R. L. Guerrant, C. T. Franck, and D. M. Lyerly.** 2014. Ribotype 027 *Clostridium difficile* infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. *Eur.J Clin.Microbiol.Infect.Dis.* **33**:1045-1051. doi:10.1007/s10096-013-2043-1 [doi].
2. **Boone, J. H., J. R. DiPersio, M. J. Tan, S. J. Salstrom, K. N. Wickham, R. J. Carman, H. R. Totty, R. E. Albert, and D. M. Lyerly.** 2013. Elevated lactoferrin is associated with moderate to severe *Clostridium difficile* disease, stool toxin, and 027 infection. *Eur.J Clin.Microbiol.Infect.Dis.* **32**:1517-1523. doi:10.1007/s10096-013-1905-x [doi].
3. **Gisbert, J. P., A. G. McNicholl, and F. Gomollon.** 2009. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. *Inflamm.Bowel.Dis.* **15**:1746-1754. doi:10.1002/ibd.20920 [doi].
4. **Gonsalves, S., M. Lim, P. Finan, P. Sagar, and D. Burke.** 2013. Fecal lactoferrin: a noninvasive fecal biomarker for the diagnosis and surveillance of pouchitis. *Dis.Colon Rectum* **56**:733-737. doi:10.1097/DCR.0b013e318280194a [doi];00003453-201306000-00008 [pii].
5. **Hayakawa, T., C. X. Jin, S. B. Ko, M. Kitagawa, and H. Ishiguro.** 2009. Lactoferrin in gastrointestinal disease. *Intern.Med* **48**:1251-1254. doi:JST.JSTAGE/internalmedicine/48.2199 [pii].
6. **Joishy, M., I. Davies, M. Ahmed, J. Wassel, K. Davies, A. Sayers, and H. Jenkins.** 2009. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. *J Pediatr.Gastroenterol.Nutr.* **48**:48-54. doi:10.1097/MPG.0b013e31816533d3 [doi];00005176-200901000-00008 [pii].
7. **Langhorst, J. and J. Boone.** 2012. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases. *Drugs Today (Barc.)* **48**:149-161. doi:1732555 [pii];10.1358/dot.2012.48.2.1732555 [doi].
8. **LaSala, P. R., T. Ekhmimi, A. K. Hill, I. Farooqi, and P. L. Perrotta.** 2013. Quantitative fecal lactoferrin in toxin-positive and toxin-negative *Clostridium difficile* specimens. *J Clin.Microbiol.* **51**:311-313. doi:JCM.02735-12 [pii];10.1128/JCM.02735-12 [doi].
9. **Masoodi, I., R. Kochhar, U. Dutta, C. Vaishnavi, K. K. Prasad, K. Vaiphei, S. Kaur, and K. Singh.** 2009. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. *J Gastroenterol.Hepatol.* **24**:1768-1774. doi:JGH6048 [pii];10.1111/j.1440-1746.2009.06048.x [doi].
10. **Moscandrew, M. E. and E. V. Loftus, Jr.** 2009. Diagnostic advances in inflammatory bowel disease (imaging and laboratory). *Curr.Gastroenterol.Rep.* **11**:488-495.
11. **Pfefferkorn, M. D., J. H. Boone, J. T. Nguyen, B. E. Juliar, M. A. Davis, and K. K. Parker.** 2010. Utility of fecal lactoferrin in identifying Crohn disease activity in children. *J Pediatr.Gastroenterol.Nutr.* **51**:425-428. doi:10.1097/MPG.0b013e3181d67e8f [doi].
12. **Sipponen, T., E. Savilahti, P. Karkkainen, K. L. Kolho, H. Nuutinen, U. Turunen, and M. Farkkila.** 2008. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. *Inflamm.Bowel.Dis.* **14**:1392-1398. doi:10.1002/ibd.20490 [doi].
13. **Sipponen, T., E. Savilahti, K. L. Kolho, H. Nuutinen, U. Turunen, and M. Farkkila.** 2008. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. *Inflamm.Bowel.Dis.* **14**:40-46. doi:10.1002/ibd.20312 [doi].
14. **Yamamoto, T., M. Shiraki, T. Bamba, S. Umegae, and K. Matsumoto.** 2014. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. *Int.J Colorectal Dis.* **29**:485-491. doi:10.1007/s00384-013-1817-3 [doi].